CenterBook Partners’s 10x Genomics TXG Stock Holding History

CenterBook Partners’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-230,772	Closed	-$3.76M	–	783
2025 Q4	$3.76M	Buy	+230,772	New	+$3.49M	0.18%	155

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CenterBook Partners's TXG Position: Q1 2026 in Review

CenterBook Partners sold out of 10x Genomics (TXG) in Q1 2026, closing a stake of 230,772 shares — an estimated $3.76M sold.

CenterBook Partners first reported a position in TXG in Q4 2025 and held it in 1 quarter. The position peaked at $3.76M in Q4 2025. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

CenterBook Partners reported no remaining 10x Genomics position as of Q1 2026 after selling out during the quarter.
CenterBook Partners sold 230,772 10x Genomics shares in Q1 2026, an estimated $3.76M.
CenterBook Partners first reported a position in 10x Genomics in Q4 2025 and held it in 1 quarter.
CenterBook Partners's 10x Genomics position peaked at $3.76M in Q4 2025.
329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on CenterBook Partners's 13F filing for Q1 2026, filed 5 May 2026.